Index

abraxane, 469
adaptive proton therapy, 347
adaptive signature design (ASD) for trials, 499–500
adenocarcinoma in situ (AIS), 145–7
adenocarcinoma of the lung, 144
classification in resected specimens
adenocarcinoma in situ (AIS), 145–7
atypical adenomatous hyperplasia (AAH), 145
minimally invasive adenocarcinoma (MIA), 147–50
preinvasive lesions, 145–50
proposed IASL/ATS/ERS classification, 146
classification in small biopsies and cytology, 151–4
histologic classification, 145
invasive adenocarcinoma, 150
prognosis, 151
TNM staging, 151
variants, 150
pathogenesis, 116–18
preneoplasia, 113
adenoid cystic carcinoma, 268
adenoma of the lung genomics, 68
cell cycle and TP53 circuits, 71–2
epigenetic modifier circuits, 73
future directions, 74
gene expression profiling, 74
mutations, 70
prognostic factors, 73
molecular alteration spectra, 68–9
motility circuits, 72–3
proliferation circuits, 69–71
viability circuits, 72
adjuvant chemotherapy following surgery, 278
clinical trials, 278–9
Adjuvant Lung Project Italy (ALPI), 280
Adjuvant Navelbine International Trialist’s Association Study (ANITA), 282–3
Big Lung Trial, 281–2
Cancer and Leukemia Group B (CALGB), 283
International Adjuvant Lung Cancer Trial (IALT), 280–81
Japanese Clinical Oncology Group Trial 279–80
JBR 10 Trial, 282
pooled analyses, 283–4
patient selection
elderly patients, 285
poor performance status patients, 285
stage IA disease, 284
stage IB disease, 284
stage II and III disease, 284
regimen selection
cisplatin versus carboplatin, 285
second agent choice, 285
summary of recommendations, 286–7
unanswered questions
predictive and prognostic biomarkers, 286
targeted therapies, 286
afatinib, 415
EGFR-resistant mutations, 423
survival outcomes, 441
afibbercept, 534–5
airway stents, 256
ALK rearrangements, 541, 550–51
clinicopathologic features, 543
crizotinib (ALK inhibitor), 546
acquired resistance, 548–9
clinical efficacy, 546–8
safety profile, 548
trials, 546
diagnostic tests, 544
ALK FISH, 544–5
immunohistochemistry, 545–6
RT-PCR, 545
heat shock protein 90 (HSP90) inhibitors, 550
molecular biology, 541–2
next generation ALK inhibitors, 549
AP26113, 549–50
ASP3026, 550
CH5424802, 550
LDK378, 549
other systemic therapies, 549
prognostic implications, 544
role of EML4-ALK in molecular pathogenesis, 542–3
altered fractionation, 379, 386
advances in technology and conformality, 381–3
phase III trials, 382
history, 379–81
modern studies, 383–4
planning individualized treatment, 385–6
American Association for Thoracic Surgery (AATS) guidelines, 182–3, 184
amplification refractory mutation system (ARMS), 442
anaplastic large cell lymphoma (ALCL), 542
anaplastic lymphoma kinase (ALK), 48, 541
inhibitors, 48
angiogenic squamous dysplasias (ASDs), 115–16
anterior mediastinoscopy, 207

antiangiogenic therapy for metastatic NSCLC, 527, 536
biomarkers, 535–6
monoclonal antibodies to VEGF/VEGFR
bevacizumab, 527–30
ramucirumab, 530
other therapies
afibercept, 534–5
small molecule TKIs, 530–31
axitinib, 533
BIBF 1120, 533–4
cabozantib, 534
cediranib, 533
motesanib, 533
pazopanib, 532
sorafenib, 531–2
sunitinib, 532
vandetanib, 532
vascular disrupting agents (VDAs), 534
antiangiogenic therapy for SCLC, 513–14, 517–18
biomarkers, 514–15
circulating cytokines, 515–16
high blood pressure (HBP), 515
other biomarkers, 516
VEGF SNPs, 516
tumor resistance, 516–17
antibody microarrays, 53
aorta, 247–9
apoptopic phenotypic assays, 35
argon plasma coagulation (APC), 137–8, 259
ASPIRE (A Smoking Prevention Interactive Experience), 8–9
asthma, 26
atypical adenomatous hyperplasia (AAH), 112, 145
adenocarcinoma, 113
pathogenesis, 116–18
detection of preneoplastic lesions, 135–6
autoantibodies, 102
autofluorescence bronchoscopy (AFB), 129, 130–31
assessment prior to endobronchial therapy, 134
indications for
abnormal sputum cytology, 133
patients with suspected, known or previously resected lung cancer, 133–4
axitinib, 512
metastatic NSCLC, 533
balloon bronchoscopy, 256
Bayesian Model Average continuous reassessment method (BMA-CRM), 493
Bayesian statistics, 491–3
behavioral counseling for smoking cessation, 10–12
efficacy, 11
Benjamini–Hochberg method, 56–7
beta-carotene dietary supplementation, 28
bevacizumab, 527–30
bexarotene
BATTLE trial, 497, 498
bias in screening, 177
BIBF 1120 (VEGFR inhibitor) metastatic NSCLC, 533–4
Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, 482–4
design schema, 497
principles, 498
statistical analysis, 496–9
biomarker signatures, 564–5
future directions, 568
predictive biomarkers, 567–8
prognostic biomarkers, 565–7
biomarker stratified Bayesian adaptive randomization design (BSBARD), 494
biomarkers, 481–2
biomarkers for LC risk and early detection
circulating DNA and promoter methylation, 36
circulating microRNA (miRNA), 35
circulating mRNAs and proteins, 36
inflammatory biomarkers, 35
telomere length, 36
biomarkers predictive for EGFR inhibitors, 435–6
EGFR gene copy numbers, 443
EGFR germline polymorphisms, 443–4
EGFR protein expression, 443
EGFR testing in clinical setting, 445–7
future perspectives, 447–8
KRAS mutations, 444
mutation detection methods, 440–43
other biomarkers, 444–5
other rare mutations, 439
resistant EGFR mutations, 438–9
role of EGFR mutations is clinical settings, 440
sensitizing EGFR mutations, 436–8
biophotonic imaging, 129–30
biopsies
transbronchial, 219
transsthoracic, 218–19
bleomycin, 33–4
blood pressure, high (HBP), 515, 535
blood proteome, 91–2
Bonferroni correction, 56
brachytherapy, 138
BRAF mutations in NSCLC, 557, 561
biology, 557–8
clinical characteristics, 559
diagnosis, 559
inactivating mutations, 560
inhibitor resistance mechanisms, 560–61
melanomas and colorectal cancers, 558–9
molecular pathogenesis, 558
non-V600E mutants, 560
treatment, 559–60
brain metastases, 572, 583
biomarkers, 582–3
pathophysiology, 572–3
prophylactic cranial irradiation (PCI), 578–81
radiation toxicity to brain, 581–2
treatment options
stereotactic radiosurgery (SRS), 573–4
surgical resection, 573
whole-brain radiation therapy (WBRT), 574
after stereotactic radiosurgery (SRS), 577–8
after surgery, 576–7
primary therapy for gross disease, 574–6
bronchioloalveolar carcinoma (BAC), 110, 113
bronchoplasty, thorascopic, 233
bronchorrhea, 169–70
bronchoscopic interventions, 253, 263
central airway disease, 253–5
mechanical interventions, 255–8
nonthermal, nonmechanical interventions, 261–3
therapeutic options, 294
thermal interventions, 258–60
tracheal tumors, 268
types, 254
bupropion SR for smoking cessation, 13–16, 18
pregnancy, 19
cabozantinib
metastatic NSCLC, 534
Cancer Genome Atlas, The (TCGA), 49
cancer immunotherapy, 454
candidate gene studies, 29
carboplatin, 279, 285
phase II trials in earlier stage disease, 295
phase II trials in resectable stage III disease prospective trials, 294
survival outcomes, 441
carbozantinib, 465–6

chronic myelogenous leukemia (CML), 488
chronic obstructive pulmonary disease (COPD), 26, 122
solitary lung nodules, 215
cigarettes, see smoking
cigars, see smoking
circulating autoantibodies, 102
circulating endothelial cells (CECs), 516, 536
circulating tumor cell (CTCs) analysis, 55
cisplatin, 279, 285
phase II trials in earlier stage disease, 295
phase II trials in resectable stage III disease prospective trials, 293–4
survival outcomes, 440
Clara cells, 113, 145
clinical target volume (CTV), 326, 362
combination EGFR inhibitors with chemotherapy, 406–8
combination radiation therapy with chemotherapy for NSCLC and carcinoma, 353, 371
chemoradiation for small-cell lung cancer, 367
chemotherapy regimens, 368
concurrent chemoradiation followed by surgical resection, 357–9
concurrent chemotherapy and radiation therapy trials, 356
consolidative thoracic radiation for extensive-stage disease, 370
continuous hyperfractionated, accelerated radiation treatment (CHART), 366

comet assay, 34
computed tomography (CT)
cone-beam CT (CBCT), 313–14
distant metastasis (M), 196–7
imaging lung cancer, 191–2
in-room CT, 315
megavoltage cone-beam CT (MVCT), 313
regional lymph nodes (N), 192–5
screening, 178–9
staging of the mediastinum, 202–3
integrated PET-CT, 202–3
tracheal tumors, 269
conformal radiation therapy (CRT), 339
consolidative thoracic radiation for extensive-stage disease, 370

continuous hyperfractionated, accelerated radiation treatment (CHART), 380–81, 391
continuous reassessment method (CRM), 493
copy number assessment, 51
coronal multiplanar reformat, 269
cranial irradiation, prophylactic, 370–71
C-reactive protein (CRP), 35
crizzitinib, 60, 546
acquired resistance, 548–9
clinical efficacy, 546–8
multifocal bronchioloalveolar carcinoma (BAC), 169
safety profile, 548
total 546
cryorecanalization, 260
cryotherapy, 138, 259–60
Cyberknife system, 315
cyclophosphamide, 278
cytokine and angiogenic factors (CAFs), 515, 536
cytotoxic T-lymphocytes (CTLs), 456, 457–8

Index 593
dacomitinib, 414–15
EGFR-resistant mutations, 423
data analysis for molecular profiling, 55–8
dendritic cell (DC) vaccines, 457–8
detection, early, in molecular profiling, 58–9
diagnosis in molecular profiling, 58–9
diaphragm involvement, 245
diet and nutritional risk factors for lung cancer
betacarotene dietary supplementation, 28
carotenoids, 27–8
folic acid, 28
fruit and vegetable intake, 27
phytoestrogens, 28
diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), 113
disease control rate (DCR), 480, 482–3, 496–7
DNA analysis techniques, 49
sequencing, 50–51
DNA adducts assay, 34
DNA damage and repair assays, 33
comet assay, 34
DNA adducts assay, 34
gamma-H2AX assay, 34
host cell reactivation assay, 34
mutagen sensitivity assay, 33–4
8-OGG assay, 34
DNA damage repairing drugs, 395–6
docetaxel, 466
phase II trials in resectable stage III disease prospective trials, 293
Doll, Sir Richard, 3
dose escalation, 379, 386
advances in technology and conformality, 381–3
phase III trials, 382
history, 379–81
modern studies, 383–4
planning individualized treatment, 385–6
dose spillage, 326
dose-volume histograms (DVHs), 362
double-strand breaks (DSBs), 34
docetaxel in phase II trials for earlier stage disease, 295
doxorubicin, 278
driver alterations, 68
dynamic treatment regimen (DTR) for trials, 500–501
dysphagia accompanying tracheal tumors, 268
echinoderm microtubule-associated protein-like, 4-anaplastic lymphoma kinase (EML4-ALK) fusion, 48
role in molecular pathogenesis, 542–3
education
behavioral counseling, 10–12
smoking cessation interventions, 10
efficacy, 11
EGFR inhibitors
predictive tumor biomarkers, 435–6
EGFR gene copy numbers, 443
EGFR germline polymorphisms, 443–4
EGFR protein expression, 443
EGFR testing in clinical setting, 445–7
future perspectives, 447–8
KRAS mutations, 444
other biomarkers, 444–5
other rare mutations, 439
resistant EGFR mutations, 438–9
role of EGFR mutations is clinical settings, 440
sensitizing EGFR mutations, 436–8
electrocautery, 137–8, 258–9
Electromagnetic Navigation (EMN), 135
electromagnetic navigation bronchoscopy (ENB), 219
electronic cigarettes (e-cigarettes), 7
electrospray ionization (ESI), 54
emphysema, 26
endobronchial brachytherapy (EBBT), 138, 262–3
endobronchial cryotherapy, 259–60
endobronchial electrocautery, 258–9
endobronchial therapies, 137
brachytherapy, 138
cryotherapy, 138
electrocautery, 137–8
follow-up, 138
photodynamic therapy (PDT), 137
endobronchial ultrasound with transbronchial fine needle aspiration (EBUS-TBNA or EBUS-FNA), 203–5, 208–9
endoscopy staging of the mediastinum, 203–5
endotracheal ultrasonography (EU), 268–9
environmental tobacco smoke (ETS), 25
enzyme-linked immunosorbent assay (ELISA), 54
epidemiologic risk factors for lung cancer, 25
diet and nutritional risk factors betacarotene dietary supplementation, 28
carotenoids, 27–8
folic acid, 28
fruit and vegetable intake, 27
phytoestrogens, 28
family history, 25–6
prior inflammatory diseases and disorders
asthma, 26
COPD, 26
emphysema, 26
hay fever, 26
epidermal growth factor receptor (EGFR) inhibitors, 48, 406, 416
combination therapy with chemotherapy, 406–8
intermittent therapy with chemotherapy, 408
maintenance therapy, 412–13
salvage therapy, 413–14
single agent, 409–12
signaling, 507
targeting, 393–4
epidermal growth factor receptor (EGFR) resistance, 421–2, 429
acquired EGFR mutations, 425–7, 436
epithelial-mesenchymal transition (EMT), 428
HER2 amplification, 427
HGF overexpression, 428
histological transformation, 428
IGF-1 signaling and other pathways, 428
MAPK1 amplification, 427
MET amplification, 427–8
pharmacologic interactions, 428–9
tumor heterogeneity, 429
acquired resistance to TKIs, 425
primary resistance to TKIs, 422
EGFR-resistant mutations, 422–4
ErbB family mutation and amplification, 425
KRAS and BRAF mutations, 424
PIK3CA mutations and PTEN loss, 424–5
epithelial-mesenchymal transition (EMT), 428
epothilone, 469
erbulin, 469
erlotinib, 60, 61
BATTLE trial, 497, 498
EGFR-resistant mutations, 422–3
front-line therapy, 406
multifocal bronchioloalveolar carcinoma (BAC), 169
survival outcomes, 441
etoposide, 279
everolimus, 467
extended cervical mediastinoscopy, 207
extracorporeal membrane oxygenation (ECMO), 274
false discovery rate (FDR), 56–7
family history, 25–6
fibroblast growth factors (FGFs), 507
flexible bronchoscopy, 255–6
flip-flop trials, 399
fluorescence bronchoscopy, 268
fluorescent in situ hybridization (FISH), 51
fluoro-dioxide-glucose positron emission tomography (FDG-PET), 193–5, 196
image-guided radiation therapy, 319
solitary pulmonary nodules, 217–18
staging of the mediastinum, 202–3
folate/folic acid, 28
fruit intake, 27
gamma-H2AX assay, 34
ganetesib, 464–5
gefitinib
EGFR-resistant mutations, 422–3
survival outcomes, 441
gemcitabine
phase II trials in earlier stage disease, 295
phase II trials in resectable stage III disease prospective trials, 293–4
genetic risk factors for lung cancer, 28–9
candidate gene approaches, 29
chromosome 12p13, 31–2
chromosome 15q25.1, 30–31
chromosome 5p15.33, 31
chromosome 6p21, 31–2
gene expression association studies (GWAS), 29–30
intermediate phenotypic assays
apoptotic phenotypic assays, 35
cell cycle phenotypic assays, 35
DNA damage and repair assays, 33–4
novel biomarkers for LC risk and early detection, 35–6
never-smokers, 32–3
racial subgroup, 32
summary of susceptibility loci, 33
tumor histology, 32
gene-wide association studies (GWAS), 29–30
adenoma of the lung, 74
summary of LC susceptibility loci, 33
genomics, 50
whole-genome sequencing, 51
gross target volume (GTV), 312, 326, 362
ground glass nodule (GGN), 147, 160, 166, 167
ground glass opacities (GGOs), 183
GSTM1 gene, 29
guided transbrachial biopsy, 219
hay fever, 26
HCF inhibitors, 465–6
heart and great vessels, 247–9
heat shock protein (HSP90) inhibitors, 397–8, 463–4, 549
hedgehog inhibitors, 468–9
high blood pressure (HBP), 515, 535
high dose spillage, 326
hookah smoking, 7
hoarseness accompanying tracheal tumors, 268
host cell reactivation assay, 34
hypertension, 515, 535
hypoxia inducible factor-1α (HIF-1α), 506
hypoxia targeting, 391–3
ifosfamide
phase II trials in resectable stage III disease prospective trials, 294
image-guided radiation therapy, 309, 316
background, 313
cone-beam CT, 313–14
conventional versus CT-based simulation, 310
in-room CT, 315
markers, 314–15
orthogonal kV X-rays, 315
PET and PET-CT in treatment planning, 310–12
respiratory gating, 315
role in SBRT, 316
tomotherapy, 314
tumor motion, 312–13
imaging lung cancer, 191, 199
distant metastasis (M), 195–9
primary tumor (T), 191–2
regional lymph nodes (N), 192–5
staging of the mediastinum, 202–3
immunologic approaches, 460–61
cancer immunotherapy, 454
dendritic cell vaccines, 457–8
gene delivery vaccines, 460
gene adjuvant vaccines, 459–60
modified tumor cell vaccines, 458–9
targeting regulatory checkpoints, 454–5
tumor protein and peptide vaccines, 455–7
individualized radiotherapy, 379, 386
advances in technology and conformality, 381–3
phase III trials, 382
history, 379–81
modern studies, 383–4
planning, 385–6
inflammation and lung cancer, 122
inflammatory biomarkers, 35
inflammatory diseases and disorders associated with lung cancer
asthma, 26
COPD, 26
emphysema, 26
hay fever, 26
in-room CT, 315
intensity modulated radiation therapy (IMRT), 309, 339, 343–4, 345
combination with chemotherapy, 366

tumor motion considerations, 347
intercellular adhesion molecule (ICAM), 98–9
intermediate dose spillage, 326
internal target volume (ITV), 312
Internet-based anti-smoking programs, 8–9
isothiocyanates (ITCs), 27
ixabepilone, 469
Kaplan–Meier survival curves, 56
kinesin protein inhibitors, 470
lapatinib, 61, 416
large-cell neuroendocrine cancer (LCNEC) of the lung genomics, 77
previous molecular findings, 77–8
laryngeal nerve involvement, 246
laser bronchoscopy, 258
lead time bias, 177
length time bias, 177
lepidic predominant adenocarcinoma (LPA), 150, 158
lethal–potentially lethal (LPL) model, 323
linear energy transfer (LET), 339
linear-quadratic relationship between radiation dose and cell survival, 323
liquid chromatography tandem mass spectrometry (LC MS/MS), 99–101
lobectomy, right and left upper, 224–5
loss-of-function NOTCH1 mutations, 77
low dose computed tomography (LDCT), 178
cost effectiveness, 186
risks
psychological and procedural risks, 186
radiation, 185
lung cancer in never-smokers (LCINS), 32–3
lymph node map, 206
lymphadenectomy, thorascopic, 233
magnetic resonance imaging (MRI)
primary tumor (T), 191–2
regional lymph nodes (N), 193
tracheal tumors, 269
mass spectrometry (MS), 53–4
matrix-assisted laser desorption/ionization (MALDI), 54
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for serum proteomic biomarkers, 92–8
maximum tolerated dose (MTD), 493
mechanical bronchoscopy, 255–8
mediastinum staging, 202, 208–10
algorithm, 210
diagnostic evaluation, 203–5
imaging, 202–3
mediastinoscopy, 205–7
variants, 207
video-assisted mediastinal lymphadenectomy (VAMLA), 208
megavoltage cone-beam CT (MVCBCT), 313
MEK inhibitors, 466
melanoma-associated antigen (MAGE), 456–7
MET inhibitors, 465–6
metastasis imaging, 195–9
occult metastases, 197
methylation profiling, 51
microarrays (oligonucleotide arrays), 52
microdebrider bronchoscopy, 258
microRNA (miRNA), 35, 52
minimally invasive adenocarcinoma (MIA), 147–50
mitogen activated kinase (MAPK) pathway, 69–70
mitomycin, 279
mitotic inhibitors, 469–70
molecular profiling, 48–50
analysis modes, 49
clinical applications, 58
data analysis and statistics, 55–8
DNA sequencing, 50–51
early detection and diagnosis, 58–9
future directions, 61–2
proteomics, 53–5
RNA profiling, 51–3
subclassication and staging, 59–60
techniques, 50
therapy selection, 60–61
molecular target therapy, 401
challenges and opportunities, 401
clinical trial considerations
preclinical studies, 398–9
prioritizing agents, 398
synthetic lethality effect with radiation, 398
trial design, 399–401
EGFR targeting, 393–4
guidelines, 394–5
cell cycle checkpoint inhibitors, 396
DNA damage repairing drugs, 395–6
epigenetic agents, 396–7
HSP90 inhibitors, 397–8
potential agents combined with radiation therapy, 395
signal transduction inhibitors, 396
hypoxia targeting, 391–3
overcoming plateau of radiation efficacy, 391
targeted therapy with radiotherapy, 391
technologic improvements, 390–91
vascular targeting, 393
monoclonal antibodies (MAbs), 406, 414–16
VEGF/VEGFR
bevacizumab, 527–30
ramucirumab, 530
motesanib, 512
metastatic NSCLC, 533
mucin-1 (MUC1) 457, 458
mucinous bronchioloalveolar carcinoma (BAC), 144, 150
multidetector spiral computer tomography (CT), 129
multifocal bronchioloalveolar carcinoma (BAC), 158, 170–71
approach to unifocal progression in multifocal disease, 164–5
bronchorrhea, 169–70
evaluation, 159–60
natural history, 160–61
symptomatology, 160
heterogeneity in presentation, 159
management, 161
algorithm, 162
location, 161–3
Index 597

symptoms and progression, 163
unifocal or multifocal progression, 163–4
palliative surgery, 165
systemic therapy, 165–9
multiplex bead-based assay, 54–5
mutagen sensitivity assay, 33–4
mutation detection methods, 440–43
mutation spectrums for never-smokers and smokers, 60
narrow band imaging (NBI), 131
National Lung Screening Trial (NLST), 179
design, 179–80
participant cohort, 180
results, 180–81
Nd-YAG laser therapy, 137
neucitumumab, 415–16
neoadjuvant chemotherapy for resectable NSCLC, 290–91, 304–5
five-year survival, 291
impact on surgical morbidity and mortality, 300–301
meta-analyses, 299–300
phase II trials in earlier stage disease prospective trials, 294
phase II trials in resectable stage III disease, 291–4
randomized phase II and phase III trials, 295–9
surrogate efficacy endpoints, 301–2
window of opportunity trials, 302–4
neratinib
EGFR-resistant mutations, 423, 424
neuroendocrine tumors, 113
never-smokers, 32–3
mutation spectrum, 60
next-generation sequencing (NGS), 120, 123
nicotine addiction, 9
nicotine replacement therapy (NRT) medications, 13–16, 17
pregnancy, 19
nintedanib, 512
nitrosourea, 278
nodules
prevalence, 214–15
solitary, see solitary pulmonary lung nodule
N-of-1 design for trials, 500
nonmucinous bronchioloalveolar carcinoma (BAC), 150
non-small squamous cell lung cancers (NSCLCs), see also neoadjuvant chemotherapy for resectable NSCLC
BRAF mutations, 557, 561
biology, 557–8
clinical characteristics, 559
diagnosis, 559
inactivating mutations, 560
inhibitor resistance mechanisms, 560–61
melanomas and colorectal cancers, 558–9
molecular pathogenesis, 558
non-V600E mutants, 560
treatment, 559–60
classification, 59–60
combination radiation therapy with chemotherapy, 353
imaging, 191
distant metastasis (M), 195–9
primary tumor (T), 191–2
regional lymph nodes (N), 192–5
proton therapy, 338–9
staging, 237
notch inhibitors, 467
novel clinical trial designs for metastases, 479
alternative endpoints, 479–80
BATTLE trial, 482–4
impact of molecularly targeted agents on designs, 481–2
implementing innovative designs, 484–5
need for novel designs, 480–81
novel and emerging agents, 464
targeted agents
future directions, 470
heatshock protein, 90 (HSP90) inhibitors, 464–5
MEK inhibitors, 466
MET inhibitors/HGF inhibitors, 465–6
mitotic inhibitors, 469–70
notch and hedgehog inhibitors, 468–9
PARP inhibitors, 468
PI3K/AKT/mTOR pathway inhibitors, 466–8
targeted gene therapy, 470–71
future directions, 474
gene replacement combined with chemotherapy and radiation, 472–3
p53 gene replacement, 471
systemic gene therapy for metastases, 473–4
novel statistical models for clinical trials, 488–9, 501–2
adaptive designs, 493
biomarker stratified Bayesian adaptive randomization design (BSBARD), 494 challenges, 496
comparison of standard and novel designs, 494–6
continuous reassessment method (CRM), 493
predictive probability design (PPD), 493–4
BATTLE trial case study, 496–9
Bayesian statistics, 491–3
other novel designs, 499–501
adaptive signature design (ASD), 499–500
adaptive threshold design (ASD), 500
dynamic treatment regimen (DTR), 500–501
N-of-1 design, 500
platform designs, 501
randomized discontinuation design (RDD), 500
seamless phase II/III designs (SP23D), 500
nucleotide exclusion repair (NER), 33
nutrition, see diet and nutritional risk factors for lung cancer
objective response rate (ORR), 406
occult metastases, 197
olaparib, 468
oligonucleotide arrays (microarrays), 52
onartuzumab, 416, 465
oncogene addition, 421
oncothyreon, 467
optical coherence tomography (OCT), 129, 131–2
orthogonal kV X-rays, 315
overall survival (OS), 479–80, 484–5
overdiagnosis bias, 177
overtraining of data, 57
8-oxoguanine (8-OGG) assay, 34
Index

paclitaxel, 469
phase II trials in earlier stage disease, 295
phase II trials in resectable stage III disease prospective trials, 294
pain, postoperative, 226
passenger alterations, 68
passive smoking, 3
pazopanib metastatic NSCLC, 532
VEGFR pathway inhibition, 511–12
pericardium, 246–7
peripheral blood lymphocytes (PBLs), 33
peripheral nodules, 220–21
pharmacotherapy interventions for smoking cessation, 12–16
bupropion SR, 13–16, 18
combination therapy, 19
efficacy, 11
nicotine replacement therapy (NRT) medications, 13–16, 17
pregnancy, 19
varenicline, 13–16, 18–19
phenotypic assays to measure genetic susceptibility
DNA damage and repair assays, 33
8-OGG assay, 34
comet assay, 34
daDNA adducts assay, 34
gamma-H2AX assay, 34
host cell reactivation assay, 34
mutagen sensitivity assay, 33–4
Philadelphia chromosome, 487
photodynamic therapy (PDT), 137, 261–2
photon radiotherapy, 338
phrenic nerve involvement, 245–6
phytoestrogens, 28
PI3K/AKT/mTOR pathway inhibitors, 466–8
ping-pong trials, 399
pipe smoking, see smoking
planning target volume (PTV), 312, 326, 362
platelet derived growth factors (PDGFs), 507–8
platform designs for trials, 501
pneumonectomy, thorascopic, 233
polo-like kinase (PLK), 470
polypropylene mesh reconstruction, 240
positron emission tomography (PET), 191
FDG-PET, 193–5, 196
solitary pulmonary nodules, 217–18
staging of the mediastinum, 202–3
image-guided radiation therapy, 311
imaging distant metastasis (M), 196–7
PET-CT
image-guided radiation therapy, 311
staging of the mediastinum, 202–3
postoperative pain, 226
potentially reduced-exposure tobacco products (PREPs), 6–7
predictive biomarker signatures, 567–8
predictive probability design (PPD), 493–4
predictive tumor biomarkers for EGFR inhibitors, 435–6
EGFR gene copy numbers, 443
EGFR germline polymorphisms, 443–4
EGFR protein expression, 443
EGFR testing in clinical setting, 445–7
future perspectives, 447–8
KRAS mutations, 444
mutation detection methods, 440–43
other biomarkers, 444–5
other rare mutations, 439
resistant EGFR mutations, 438–9
role of EGFR mutations is clinical settings, 440
sensitizing EGFR mutations, 436–8
predictors of smoking initiation, 7, 9
predisposition to lung cancers and adenoma, 73–4
pregnancy and smoking cessation medications, 19
preneoplasia, 110–11
field carcinization compartmentalization, 120–22
field carcinization in pathogenesis, 118–19
smoking damaged epithelium, 119
transcriptome, 119–20
inflammation, 122
molecular pathogenesis of lung cancer, 114–15
adenocarcinoma, 116–18
histological and molecular abnormalities, 114
small cell lung cancer (SCLC), 118
squamous cell carcinoma (SqCC), 115–16
pathology, 111
adenocarcinoma, 113
histopathological changes of lung cancer pathogenesis, 112
neuroendocrine tumors, 113
squamous cell carcinoma (SqCC), 111–13
summary, 122–3
preneoplastic lesions, detection and treatment, 129
assessment prior to endobronchial therapy, 134
central airway detection autofluorescence bronchoscopy (AFB), 130–31
biophotonic imaging principles, 129–30
narrow band imaging (NBI), 131
optical coherence tomography (OCT), 131–2
dendrochiral therapies, 137
brachytherapy, 138
cryotherapy, 138
electrocautery, 137–8
follow-up, 138
photodynamic therapy (PDT), 137
indications for autofluorescence bronchoscopy
abnormal sputum cytology, 133
patients with suspected, known or previously resected lung cancer, 133–4
peripheral lung, 135–6
preinvasive bronchial lesions, 136–7
surveillance of bronchial intraepithelial neoplasm, 134–5
prognostic biomarker signatures, 565–7
progression-free survival (PFS), 479–80
prophylactic cranial irradiation (PCI), 370–71, 572, 578–81
proteins, analysis techniques, 49
proteomics, 50, 53–5
proton beam therapy (PBT), 366–7
proton therapy, 338–9
normal-tissue doses
clinical trials, 349–50
lower doses than 3D-CRT, IMRT
and SBRT, 347–9
rationale, 340–41
relative biological effectiveness
(RBE), 339–40
treatment planning and delivery
adaptive proton therapy, 347
dynamic spot scanning systems,
343–4
image-guided proton delivery,
346
passive scattering systems,
341–3
physical characteristics of proton
beams, 341
planning proton versus photon
therapy, 344–5
tumor motion considerations,
346–7
QuitMedKit© app, 12
racial subgroup susceptibility to lung
cancer, 32
radial endobronchial
ultrasound-guided sheath, 219
radial endoscopic ultrasound
(R-EBUS), 135
radiology, 176, 187
cost effectiveness of LDCT
screening, 186
historical perspective, 177–8
computed tomography (CT)
screening, 178–9
radiographic screening, 178
individualized radiotherapy, 379,
386
advances in technology and
conformality, 381–3
history, 379–81
modern studies, 383–4
planning, 385–6
National Lung Screening Trial
(NLST), 179
design, 179–80
participant cohort, 180
results, 180–81
nodule detection and
management, 182–5
ongoing trials and programs, 181
risks of LDCT screening
psychological and procedural
risks, 186
radiation, 185
smoking cessation, 186
treatment from trial to practice
academy center to community
hospital, 187
recruitment, 186–7
US recommendations, 181–2
ramucirumab, 530
randomized discontinuation design
(RDD) for trials, 500
rapamycin, 466, 467
Ras family genes and adenoma of
the lung, 68
re-do mediastinoscopy, 207
relative biological effectiveness
(RBE), 340
resections, extended, 236, 250
chest wall invasion, 238–42
outcomes, 241
diaphragm involvement, 245
general principles, 236–8
heart and great vessels, 247–9
laryngeal nerve involvement,
246
pericardium, 246–7
phrenic nerve involvement,
245–6
selection criteria, 238
staging of NSCLCs, 237
superior sulcus tumor resection,
242–3
synchronous tumors, 249–50
trachea, 249
vertebral body involvement,
243–5
resections, minimally invasive,
224–6, 233–4
adjuvant chemotherapy, 230–32
blood loss, 226–7
complications, 232
cost effectiveness, 229–30
length of stay, 229
operative time, 229
postoperative independence and
pre-operative function, 227
postoperative pain, 226
pulmonary function, 227–9
special circumstances
barriers to adoption, 232
reoperation, 232
robot-assisted lobectomy
(RATS), 233
thorascopic bronchoplasty, 233
thorascopic chest wall
resections, 233
thorascopic lymphadenectomy,
233
thorascopic pneumonectomy,
233
thorascopic segmentectomy, 232
respiratory gating, 315
response rate (RR), 479–80
retaspimycin hydrochloride, 464
reverse phase protein arrays
(RPPAs), 53
rigid bronchoscopy, 255–6
risk assessment models
current state, 37–8
overview, 36–7
RNA
analysis techniques, 49
profiling, 51–3
robot-assisted lobectomy (RATS),
233
sagittal oblique multiplanar
reformats, 269
school-based smoking prevention
programs, 8
screening for lung cancer, 176, 187
bias, 177
cost effectiveness, 186
historical perspective, 177–8
computed tomography (CT)
screening, 178–9
radiographic screening, 178
National Lung Screening Trial
(NLST), 179
design, 179–80
participant cohort, 180
results, 180–81
nodule detection and
management, 182–5
ongoing trials and programs, 181
risks
psychological and procedural
risks, 186
radiation, 185
smoking cessation, 186
translation from trial to practice
academy center to community
hospital, 187
recruitment, 186–7
US recommendations, 181–2
seamless phase II/III designs
(SP23D) for trials, 500
secondhand smoke and lung cancer, 3
segmentectomy, thorascopic, 232
selection bias, 177
self-expanding metal stents (SEMS), 256, 257
selumetinib, 466
serum proteomic biomarkers
bioanalytical validation, 101
circulating autoantibodies, 102
current challenges, 103–4
discovery platforms, 92
future clinical implications, 104–5
origin and potential clinical utility, 90–91
serum analysis for diagnosis, 92–8
approach comparison, 93
characteristics and performance, 94–5
strategies to address serum complexity, 99
liquid chromatography tandem mass spectrometry (LC-MS/MS), 99–101
targeted multiple reaction monitoring (LC-MS/MS), 101
therapy response, 98–9
validation, 92
signal transduction inhibitors, 396
single nucleotide polymorphism (SNP), 29–30, 51
small cell lung cancer (SCLC) genomics
antiangiogenic therapy, 513–14
antiangiogenic therapy biomarkers, 514–15
circulating cytokines, 515–16
high blood pressure (HBP), 515
other biomarkers, 516
VEGF SNPs, 516
classification, 59–60
genomics, 77
biological and clinical implications, 79–80
large-scale analysis studies, 78–9
previous molecular findings, 77–8
pathogenesis, 115
smoking, 1, 19
behavioral counseling, 10–12
efficacy, 11
benefits of quitting, 9–10
cessation interventions, 10
efficacy, 11
damaged epithelium, 119
economic burden, 1
factors explaining tobacco use, 7
fatalities, 1
health consequences, 2
lung cancer, 2–3
causal role, 3
secondhand smoke, 3
lung cancer patients, 4
mutation spectrums for neversmokers and smokers, 60
nicotine addiction, 9
pharmacotherapy interventions, 12–16
bupropion SR, 18
combination therapy, 19
comparison, 13–16
efficacy, 11
nicotine replacement therapy (NRT) medications, 17
pregnancy, 19
varenicline, 18–19
prevalence, 1, 4
breakdown by characteristics, 5
initiation, 7
prevention, 7–9
recent developments in tobacco market, 6–7
tobacco types
smoked tobacco, 4–6
smokeless tobacco, 6
smoking cessation and screening, 186
snuff, 6
solitary pulmonary nodule, 214, 221
malignancy risk, 215
clinical features, 215
radiographic features, 215–16
management
FDG-PET, 217–18
central location, 218
guided transbronchial biopsy, 219
high probability, 219–20
intermediate probability, 217
low probability, 216–17
mid to central nodules, 221
mid to peripheral location, 218
nonsurgical patients, 220
patient preference and shared decision-making, 216
peripheral nodules, 220
plan, 216
surgical patients, 220
tissue sampling, 218
transsthoracic biopsy, 218–19
prevalence of lung nodules, 214–15
somatic gene alterations
lung adenoma genomics, 68
cell cycle and TP53 circuits, 71–2
epigenetic modifier circuits, 73
future directions, 74
genetic correlates of sensitivity and resistance, 73
germline predisposition, 73–4
key genetic alterations, 69–73
molecular alteration spectra, 68–9
motility circuits, 72–3
proliferation circuits, 69–71
viability circuits, 72
lung squamous cell carcinoma (SqCC) genomics
gene expression, 75
overview, 74–5
pathway alterations, 76–7
somatic copy number alterations, 75–6
somatic mutations, 76
overview, 67
small cell lung cancer (SCLC) genomics
biological and clinical implications, 79–80
large-scale analysis studies, 78–9
previous molecular findings, 77–8
sorafenib
BATTLE trial, 497, 498
metastatic NSCLC, 531–2
VEGFR pathway inhibition, 510
spit tobacco, 6
spray cryotherapy (SCT), 138
spread-out Bragg peak (SOBP), 339
squamous cell carcinoma (SqCC) of the lung, 269–70
genomics
gene expression, 75
overview, 74–5
pathway alterations, 76–7
somatic copy number alterations, 75–6
somatic mutations, 76
pathogenesis, 115–16
preneoplasia, 111–13
staging of the mediastinum, 202, 208–10
algorithm, 210
endoscopic evaluation, 203–5
family history, 25–6
prior inflammatory diseases and disorders, 26
genetic risk factors, 28–9
candidate gene approaches, 29
chromosome 12p13, 31–2
chromosome 15q25.1, 30–31
chromosome 5p15.33, 31
chromosome 6p21, 31–2
genome-wide association studies (GWAS), 29–30
never-smokers, 32–3
racial subgroup, 32
summary of susceptibility loci, 33
tumor histology, 32
intermediate phenotypic assays to measure genetic susceptibility
apoptopic phenotypic assays, 35
cell cycle phenotypic assays, 35
DNA damage and repair assays, 33–4
novel biomarkers for LC risk and early detection, 35–6
synchronous tumors, 249–50
TERT gene, 31
The Cancer Genome Atlas (TCGA), 49
thermal bronchoscopy, 258–60
thoracoscopy, 207
cardiopulmonary bypass, 201
thoracic endovascular aortic stent grafting (TEVAR), 208–9
thoracic radiation therapy (3D CRT), 309–10
TP53 pathway, 71–2
trachea, 249
tracheal tumors, primary, 276
anatomy and physiology, 267–8
classification, 269–72
diagnosis, 268–9
epidemiology, 267
management, 272–4
contraindications for surgical resection, 272
pathology, 269–72
prognosis, 276
staging, 268–9, 272
surgical techniques, 274–6
symptoms, 268
transcervical extended mediastinal lymphadenectomy (TEMLA), 208, 209
transforming growth factor-β (TGF-β), 458
transthoracic biopsy, 218–19
traztuzumab, 61
tumor angiogenesis, 505, 517–18
antiangiogenic therapy biomarkers, 514–15
circulating cytokines, 515–16
high blood pressure (HBP), 515
other biomarkers, 516
VEGF SNPs, 516
antiangiogenic therapy in SCLC, 513–14
combined VEGF/R and EGFR targeted therapies, 509
epidermal growth factor receptor (EGFR) signaling, 507
fibroblast growth factor receptor signaling, 507
inhibitory therapeutic strategies, 508
novel agents, 512
platelet derived growth factor receptor signaling, 507–8
regulation, 506
tumor resistance to antiangiogenic therapy, 516–17
tyrosine kinase inhibitors (TKIs) of VEGF pathway, 509–12
vascular disrupting agents (VDAs), 512–13
vascular endothelial growth factor receptor signaling, 506–7
targeted therapies, 508–9
tumor associated antigens (TAAs), 102
tumor histology, 32
tumor motion, 312–13
tumor protein and peptide vaccines, 455–7
tyrosine kinase inhibitors (TKIs), 406, 414–16
acquired EGFR mutations, 426–8, 436
epithelial-mesenchymal transition (EMT), 428
HER2 amplification, 427
HGF overexpression, 428
histological transformation, 428
IGF-1 signaling and other pathways, 428
MAPK1 amplification, 427
MET amplification, 427–8
pharmacologic interactions, 428–9
tumor heterogeneity, 429
acquired resistance, 425
metastatic NSCLC, 530–31
axitinib, 533
BIBF 1120, 533–4
caboanitib, 534
cediranib, 533
motesanib, 533
pazopanib, 532
sorafenib, 531–2
sunitinib, 532
vandetanib, 532
primary resistance, 422
EGFR-resistant mutations, 422–4
ErbB family mutation and amplification, 425
KRAS and BRAF mutations, 424
PIK3CA mutations and PTEN loss, 424–5
single agent, 409–12
phase III trials, 411
VEGFR pathway, 509–12
unsupervised techniques, 56, 57
vaccines
dendritic cell vaccines, 457–8
gene delivery vaccines, 460
immune adjuvant vaccines, 459–60
modified tumor cell vaccines, 458–9
protein and peptide vaccines, 455–7
vadimezan, 512
vandetanib BATTLE trial, 497, 498
VEGFR pathway inhibition, 510–11
varenicline for smoking cessation, 13–16, 18–19
pregnancy, 19
vascular disrupting agents (VDAs), 512–13, 534
vascular endothelial growth factor (VEGF), 506–7
monoclonal antibodies bevacizumab, 527–30
ramucirumab, 530
single nucleotide polymorphisms (SNPs), 516
targeted therapies, 508–9
vascular targeting, 393
vegetable intake, 27
veliparib, 468
ven cava, 247–9
vandetanib for metastatic NSCLC, 532
vertebral body involvement, 243–5
video-assisted mediastinal lymphadenectomy (VAML), 208
video-assisted thoracic surgery (VATS), 164
single pulmonary nodules, 220–21
vinorelbine, 278, 279
phase II trials in resectable stage III disease prospective trials, 294
vinorelbine, 279
phase II trials in resectable stage III disease prospective trials, 294
virtual bronchoscopy navigation (VBN), 135, 219
vismodegib, 469
voice changes accompanying tracheal tumors, 268
white-light bronchoscopy (WLB), 129–30
whole-body FDG-PET, 197–9
whole-brain radiation therapy (WBRT), 572, 574
primary therapy for gross disease, 574–6
after stereotactic radiosurgery (SRS), 577–8
after surgery, 576–7
whole-exome sequencing, 51
X-ray techniques
orthogonal kV X-rays, 315